RESEARCH ARTICLE

The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: a retrospective study

Masatsune Shibutani*, Kiyoshi Maeda, Hisashi Nagahara, Tatsunari Fukuoka, Shinji Matsutani, Kenjiro Kimura, Ryosuke Amano, Kosei Hirakawa and Masaichi Ohira

Abstract

Background: Growing evidence indicates that inflammation contributes to cancer progression, and several inflammatory markers have been reported to be associated with the clinical outcomes in patients with various types of cancer. Recently, the advanced lung cancer inflammation index (ALI) has been developed as a prognostic marker in patients with lung cancer. The difference between the ALI and the inflammatory markers reported in the previous studies is that the ALI contains not only indices related to inflammation but also the body mass index (BMI), which was reported to correlate with the sarcopenic status. The aim of this study was to evaluate the prognostic significance of the ALI in patients with unresectable metastatic colorectal cancer.

Methods: We retrospectively reviewed a database of 159 patients who underwent combination chemotherapy for unresectable metastatic colorectal cancer between 2008 and 2016. The BMI was calculated by dividing the weight by height squared. The neutrophil-to-lymphocyte ratio (NLR) was calculated from a blood sample by dividing the absolute neutrophil count by the absolute lymphocyte count. The ALI was defined as follows: ALI=BMIm times serum albumin concentration/NLR.

Results: The overall survival rate was significantly worse in the low-ALI group than in the high-ALI group (p < 0.0001). Furthermore, the ALI was an independent prognostic factor for the overall survival (hazard ratio: 2.773, 95% confidence interval: 1.773–4.335, p < 0.001).

Conclusions: A newly developed prognostic marker, the ALI, was found to be a novel prognostic marker in patients with unresectable metastatic colorectal cancer as well as in patients with lung cancer.

Keywords: Metastatic colorectal cancer, Prognosis, Inflammatory marker, Body mass index

Background

Growing evidence indicates that inflammation contributes to cancer progression [1, 2], and several inflammatory markers, such as the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), Glasgow prognostic score (GPS) and the C-reactive protein-to-albumin ratio (CRP/ALB ratio), have been reported to be associated with the clinical outcomes in patients with various types of cancer, including colorectal cancer [3–10].

Recently, the advanced lung cancer inflammation index (ALI), which is based on the body mass index (BMI), serum albumin concentration and NLR, was developed as a prognostic marker in patients with lung cancer [11]. The difference between the ALI and the inflammatory markers reported in previous studies is that the ALI contains not only indices related to inflammation but also the BMI, which has been reported to correlate with the sarcopenic status [12]. Sarcopenia is an important component of cancer cachexia syndrome and...
a significant prognostic factor in patients with malignant disease [13, 14]. Although there are few patients with cachexia among the patients who undergo curative resection for colorectal cancer, patients suffering from cachexia are present in definite proportions among those with unresectable metastatic colorectal cancer. Therefore, the ALI, which contains the BMI, is thought to be a more accurate prognostic marker than others.

The aim of this study was to evaluate the prognostic significance of the ALI in patients with unresectable metastatic colorectal cancer.

Methods
Between 2008 and 2016, a total of 159 patients underwent combination chemotherapy for unresectable metastatic colorectal cancer as a first-line treatment at the Department of Surgical Oncology of Osaka City University.

Blood samples were obtained and the height and the weight were measured within a period of one week prior to the initiation of chemotherapy. We assayed the serum C-reactive protein (CRP) and albumin concentrations by a chemiluminescent immunoassay (Wako, Osaka, Japan) according to the manufacturer’s protocol. We determined the differential leukocyte count by an XE-5000 hematology analyzer (Sysmex, Kobe, Japan) according to the manufacturer’s protocol. The BMI was calculated by dividing the weight by the height squared (kg/m^2). The NLR was calculated as absolute neutrophil count divided by absolute lymphocyte count from a complete blood count with differential. The ALI was defined as follows: ALI=BMI × serum albumin concentration/NLR. The modified GPS (mGPS) was defined according to the methods of a previous report [9], using the combination of the serum CRP and albumin levels: patients with a CRP level of < 1.0 mg/dl were allocated a score of 0; those in whom the CRP and albumin levels were ≥ 1.0 mg/dl and ≥ 3.5 g/dl, respectively, were allocated a score of 1; and those in whom the CRP and albumin levels were ≥ 1.0 mg/dl and < 3.5 g/dl, respectively, were allocated a score of 2. Computed tomography (CT) was used to evaluate the skeletal muscle mass. Manual tracing using CT imaging at the level of the third lumbar vertebra was used to measure the cross-sectional areas of the right and left psoas muscle. The psoas muscle mass index (PMI) was calculated as the cross-sectional areas divided by height (cm^2/m^2).

Continuous variables were compared using the Mann-Whitney test. Survival curves were made using the Kaplan-Meier method. Patients whose follow-up was discontinued were treated as censored cases in the survival analysis. Differences in the survival curves were assessed using the log-rank test. To evaluate the prognostic factors associated with overall survival, patients whose follow-up was discontinued were treated as censored cases in the survival analysis. Differences in the survival curves were assessed using the log-rank test. To evaluate the prognostic factors associated with overall survival,

Table 1 Patients’ characteristics

| Characteristic                           | Median (range) |
|-----------------------------------------|----------------|
| Age (years)                             | 65 (18–89)     |
| Gender                                  |                |
| Male                                    | 87             |
| Female                                  | 72             |
| Performance status                      |                |
| 0                                       | 139            |
| 1                                       | 17             |
| 2                                       | 3              |
| Location of primary tumor               |                |
| Right side                              | 39             |
| Left side                               | 120            |
| Histological type                       |                |
| Well, Moderately                        | 142            |
| Poorly, Mucinous                       | 17             |
| RAS status                              |                |
| Wild type                               | 63             |
| Mutant type                             | 54             |
| Unknown                                 | 42             |
| Detection of unresectable tumor         |                |
| Synchronous                             | 106            |
| Metachronous                            | 53             |
| Number of organs affected by metastasis |                |
| One organ                               | 106            |
| Multiple organs                         | 53             |
| Peritoneal dissemination                |                |
| Negative                                | 124            |
| Positive                                | 35             |
| First-line chemotherapy regimen         |                |
| FOLFOX                                  | 74             |
| CapeOX                                  | 52             |
| FOLFIRI                                 | 25             |
| SOX                                     | 8              |
| Molecular-targeted therapy              |                |
| Bevacizumab                             | 85             |
| Cetuximab                               | 11             |
| Panitumumab                             | 7              |
| None                                    | 56             |
| BMI (kg/m^2)                            | 21.71 (15.30–33.76) |
| Serum albumin concentration (g/dl)      | 3.9 (2.5–4.9)  |
| NLR                                     | 2.41 (0.58–13.56) |
| ALI                                     | 37.92 (46.11–175.07) |

FOLFOX 5-fluorouracil+leucovorin+oxaliplatin, CapeOX Capecitabine +oxaliplatin, FOLFIRI 5-fluorouracil+leucovorin+irinotecan, SOX S-1 + oxaliplatin, NLR Neutrophil-to-lymphocyte ratio, ALI Advanced lung cancer inflammation index, BMI Body mass index
multivariate Cox proportional hazard model was applied. The association between the BMI and the PMI was evaluated by Spearman’s rank correlation coefficient. Statistical analyses were performed using the SPSS software program, version 19.0 (IBM, Armonk, NY, USA). P values of < 0.05 were considered to be statistically significant.

This research conformed to the provisions of the Declaration of Helsinki. Written informed consent for the retrospective analysis of the clinical data was obtained from all participants. This retrospective study was approved by our institutional review board (approval No.926).

Results
Patient characteristics
The baseline characteristics of the patients are shown in Table 1. Eighty-seven patients were males and 72 patients were females. The median age of the patients was 65 years (range: 18 to 89). According to the definition of the Eastern Cooperative Oncology Group performance status (PS), PS was evaluated as 0 in 139 patients, 1 in 17 patients, and 2 in 3 patients. Thirty-nine patients were right-side colorectal cancer, and 120 were left-side colorectal cancer. One hundred and six patients had single-organ metastasis, and 53 had multigorgan metastases. Oxaliplatin, irinotecan plus 5-fluorouracil/leucovorin, or the prodrug of 5-fluorouracil were administered in all patients as first-line chemotherapy. The treatment regimens, which were considered to have the same efficacy, were used for all patients in the current study [15–17]. Five-fluorouracil+leucovorin+oxaliplatin (FOLFOX) were administered in 74 patients, capcitabine+oxaliplatin (CapeOX) were administered in 52, 5-fluorouracil

| Table 2 The correlations between the ALI (and its components) and the clinicopathological factors |
|-----------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                                         | ALI Median (range) | p-value | BMI (kg/m²) Median (range) | p-value | Albumin (g/dl) Median (range) | p-value | NLR Median (range) | p-value |
| Age                                     |                 |         |                             |         |                             |         |                  |         |
| < 65                                    | 34.17 (4.68–174.81) |         | 21.73 (15.48–29.91)         |         | 4.0 (2.7–4.9)               |         | 2.66 (0.71–12.57) |         |
| ≥ 65                                    | 38.52 (4.61–175.07) | 0.367   | 21.50 (15.30–33.76)         | 0.683   | 3.8 (2.5–4.8)               | 0.023   | 2.18 (0.58–13.56) | 0.112   |
| Gender                                  |                 |         |                             |         |                             |         |                  |         |
| Male                                    | 38.42 (4.61–174.81) |         | 21.80 (15.32–29.91)         |         | 3.9 (2.5–4.7)               |         | 2.44 (0.71–13.56) |         |
| Female                                  | 36.81 (7.41–175.07) | 0.341   | 20.88 (15.30–33.76)         | 0.246   | 3.9 (2.9–4.9)               | 0.714   | 2.41 (0.58–8.85)  | 0.459   |
| Location of primary tumor               |                 |         |                             |         |                             |         |                  |         |
| Right side                              | 41.44 (4.61–175.07) |         | 22.05 (15.32–33.76)         |         | 3.9 (2.7–4.8)               |         | 1.95 (0.58–13.56) |         |
| Left side                               | 33.70 (7.41–109.73) | 0.137   | 21.39 (15.30–29.91)         | 0.628   | 3.9 (2.5–4.9)               | 0.617   | 2.53 (0.94–8.85)  | 0.069   |
| Histological type                       |                 |         |                             |         |                             |         |                  |         |
| Well, Moderately                         | 36.81 (4.61–175.07) |         | 21.50 (15.30–33.76)         |         | 3.9 (2.5–4.9)               |         | 2.48 (0.58–13.56) |         |
| Poorly, Mucinous                        | 39.39 (12.96–101.80) | 0.442   | 21.79 (16.98–27.34)         | 0.962   | 3.9 (3.2–4.6)               | 0.786   | 2.03 (1.05–4.95)  | 0.375   |
| RAS status                              |                 |         |                             |         |                             |         |                  |         |
| Wild type                               | 40.35 (4.61–109.73) |         | 21.20 (15.30–33.76)         |         | 4.1 (2.5–4.8)               |         | 2.08 (0.94–13.56) |         |
| Mutant type                             | 37.29 (4.68–175.07) | 0.203   | 21.80 (16.00–29.91)         | 0.652   | 4.0 (2.7–4.9)               | 0.829   | 2.66 (0.58–12.57) | 0.075   |
| Detection of unresectable tumor         |                 |         |                             |         |                             |         |                  |         |
| Synchronous                             | 28.98 (4.61–175.07) |         | 21.49 (16.00–33.76)         |         | 3.85 (2.5–4.8)              |         | 2.69 (0.58–13.56) |         |
| Metachronous                            | 40.43 (9.31–109.73) | 0.016   | 22.02 (15.30–29.29)         | 0.680   | 4.0 (3.1–4.9)               | 0.020   | 2.08 (0.97–6.33)  | 0.028   |
| The number of organs affected by metastasis |             |         |                             |         |                             |         |                  |         |
| One organ                               | 38.21 (7.41–175.07) |         | 21.30 (15.30–29.91)         |         | 3.9 (2.5–4.9)               |         | 2.41 (0.58–7.77)  |         |
| Multiple organs                         | 36.13 (4.61–174.81) | 0.968   | 21.80 (16.89–33.76)         | 0.535   | 3.9 (2.7–4.8)               | 0.718   | 2.48 (0.71–13.56) | 0.930   |
| Peritoneal dissemination                |                 |         |                             |         |                             |         |                  |         |
| Negative                                | 35.42 (7.41–175.07) |         | 21.60 (15.30–33.76)         |         | 3.9 (2.5–4.9)               |         | 2.52 (0.58–8.85)  |         |
| Positive                                | 39.39 (4.61–98.33) | 0.365   | 21.86 (16.98–25.65)         | 0.339   | 4.0 (2.7–4.7)               | 0.190   | 2.04 (0.94–13.56) | 0.282   |
| Molecular targeted therapy              |                 |         |                             |         |                             |         |                  |         |
| Without                                 | 35.15 (11.17–174.81) |         | 22.44 (16.12–33.76)         |         | 3.85 (2.5–4.8)              |         | 2.42 (0.71–6.07)  |         |
| With                                    | 38.42 (4.61–175.07) | 0.977   | 21.00 (15.30–29.91)         | 0.105   | 4.0 (2.7–4.9)               | 0.281   | 2.41 (0.58–13.56) | 0.986   |

ALI: Advanced lung cancer inflammation index, BMI: Body mass index, NLR: Neutrophil to lymphocyte ratio
leucovorin+irinotecan (FOLFIRI) were administered in 25, and S-1 + oxaliplatin (SOX) were administered in 8. Molecular-targeted drug in combination with cytotoxic drugs was administered in 103 patients. The median duration of follow-up was 21.6 months (range: 1.2 to 94.0 months). Forty-eight patients were alive at the end of the follow-up period, and 111 patients died during the follow-up period.

Relationships between the ALI (and its components) and clinicopathological factors
Table 2 shows the relationship between the ALI (and its components) and the clinicopathological factors. The ALI had no significant relationship with any of the clinicopathological factors, with the exception of the timing of the detection of metastatic tumors.

Classification according to the ALI
The ALI, which is a continuous variable, was used as the test variable, and the 24.4-month survival (median survival time: 24.4 months) was used as the state variable. We set 28.9 (sensitivity: 72.7%; specificity: 53.8%) as the cut-off value for the ALI by calculating the receiver operating characteristic (ROC) curve (Fig. 1). The patients were classified into high-ALI \( (n = 92) \) and low-ALI \( (n = 67) \) groups.

Survival analyses according to the ALI
The overall survival rate for the low-ALI group was significantly lower than that for the high-ALI group \( (p < 0.0001) \) (Fig. 2).

Prognostic factors influencing the overall survival
The correlations between the overall survival and the various clinicopathological factors are shown in Table 3. The univariate analysis showed that the overall survival was significantly associated with the performance status \( (p = 0.021) \), the location of the primary tumor \( (p = 0.002) \), the RAS status \( (p = 0.018) \) and the ALI \( (p < 0.001) \). A multivariate analysis of these significant variables indicated that the location of the primary tumor (hazard ratio: 2.441, 95% confidence interval: 1.427–4.175, \( p = 0.001 \)) and the ALI (hazard ratio: 2.773, 95% confidence interval: 1.773–4.335, \( p < 0.001 \)) were independently associated with the overall survival.

Survival analysis according to the mGPS
Although there was no significant difference in the overall survival between the patients with an mGPS of 1 and those with an mGPS of 2, the overall survival rate of patients with an mGPS of 0 was significantly better than that of those with an mGPS of 1 or 2 (Fig. 3).
Survival analysis according to the BMI
The overall survival rate for the low-BMI group was significantly lower than that for the high-BMI group ($p = 0.0136$) (Fig. 5). Furthermore, we performed a survival analysis according to the combination of the BMI and the NLR. We set 3.0 as the cut-off NLR according to a previous report [18]. In the high BMI group, the overall survival rate of the high NLR group was significantly worse than that of the low NLR group ($p = 0.0358$). Similarly, in the low BMI group, the overall survival rate of the high NLR group was significantly worse than that of the low NLR group ($p = 0.0003$) (Fig. 6). The combination of the BMI and the NLR had greater prognostic value than the BMI alone.

Relationship between the BMI and the PMI
The BMI was significantly associated with the PMI ($r = 0.437$, $p < 0.001$) (Fig. 7).

Relationship between the ALI and tolerance of chemotherapy
There was no significant relationship between the ALI and the discontinuation of chemotherapy due to the Grade $\geq 3$ adverse events (Table 4).

Discussion
In this study, we investigated the prognostic significance of the ALI as a marker for predicting the prognosis in

Table 3  The correlations between the overall survival and various clinicopathological factors

| Univariate analysis | Multivariate analysis |
|--------------------|----------------------|
| Hazard ratio | 95% CI | $p$-value | Hazard ratio | 95% CI | $p$-value |
| Age (≥65 vs. < 65 years) | 1.266 | 0.869–1.845 | 0.219 | 1.501 | 0.767–2.936 | 0.236 |
| Gender (Female vs. Male) | 1.300 | 0.895–1.888 | 0.169 | 2.441 | 1.427–4.175 | 0.001 |
| Performance status (≥1 vs. 0) | 1.847 | 1.098–3.106 | 0.021 | 1.416 | 0.902–2.222 | 0.131 |
| Location of primary tumor (Right side vs. Left side) | 1.985 | 1.273–3.094 | 0.002 | 1.156 | 0.732–1.824 | 0.534 |
| Histological type (Poorly, Mucinous vs. Well, Moderately) | 0.710 | 0.368–1.370 | 0.307 | 1.148 | 0.783–1.684 | 0.480 |
| RAS status (Wild type vs. Mutant type) | 1.697 | 1.095–2.628 | 0.018 | 1.087 | 0.723–1.635 | 0.687 |
| Detection of unresectable tumor (Synchronous vs. Metachronous) | 1.142 | 0.770–1.693 | 0.509 | 1.087 | 0.723–1.635 | 0.687 |
| Number of organs affected by metastasis (≥2 vs. 1) | 1.142 | 0.770–1.693 | 0.509 | 1.087 | 0.723–1.635 | 0.687 |
| Peritoneal dissemination (Positive vs. Negative) | 1.156 | 0.732–1.824 | 0.534 | 1.148 | 0.783–1.684 | 0.480 |
| Molecular-targeted therapy (Absent vs. Present) | 1.156 | 0.732–1.824 | 0.534 | 1.148 | 0.783–1.684 | 0.480 |
| ALI (Low vs. High) | 2.571 | 1.754–3.769 | < 0.001 | 2.773 | 1.773–4.335 | < 0.001 |

CI: Confidence interval, ALI: Advanced lung cancer inflammation index
patients with unresectable metastatic colorectal cancer. In previous studies, the ALI has only been validated for its usefulness in patients with lung cancer. To our knowledge, this is the first study to assess the prognostic significance of the ALI in patients with colorectal cancer.

Inflammation is known to play an important role in cancer progression, and there have been a lot of reports regarding the utility of the inflammatory markers as a prognostic marker for cancer patients. Systemic inflammation in cancer patients is caused by several mechanisms, such as tissue inflammation induced by tumor growth or invasion, necrosis and local tissue damage and the production of inflammatory mediators induced by the cancer itself and leukocytes [1, 19, 20]. Because systemic inflammation is responsible for cancer growth, invasion, metastasis and resistance to chemotherapy [1, 19, 21], the measurement of the inflammatory markers has prognostic value in cancer patients.

The BMI has been reported to be associated with the presence of sarcopenia, which is an important component of cancer cachexia syndrome and a significant prognostic factor in cancer patients [12–14]. In this study, a significant correlation was found between the BMI and the PMI, which was reported to be correlated with the skeletal muscle mass of the whole body [22] and which is one of the indicators of sarcopenia. However, the BMI cannot accurately reflect the body composition, such as body fat and skeletal muscle, which are necessary for evaluating sarcopenia. There are some patients with sarcopenic obesity who have heavy weight but low muscle mass. Therefore, Kim et al. developed the modified-ALI, based on the quantitative assessment of skeletal muscle, for use instead of the BMI [23]. Nevertheless, the modified-ALI had no additional prognostic value beyond the original ALI [23]. Thus, Kim et al. concluded that the original-ALI, which was easy to calculate, was sufficient for predicting the prognosis in clinical practice. In the present study, even the BMI alone was associated with survival. However, the combination of the BMI and the NLR had greater prognostic value. As cachexia is a consequence of chronic systemic inflammation, the combination of the BMI and inflammatory markers enables a more accurate assessment of cachexia. Thus, the ALI, which includes the BMI and inflammatory markers, has excellent prognostic value.

In addition to the ALI, various inflammatory markers have been reported to be correlated with the prognosis of patients with various types of malignancies. In this study as well as the previous reports, the mGPS was found to be correlated with the prognosis of patients with unresectable metastatic colorectal cancer, and there is no doubt that the mGPS is a useful prognostic marker.
However, as mentioned in past reports, when the mGPS is used, many cases are classified into the group with an mGPS of 0, which is considered to have a good prognosis [9]. Even in this study, which contained advanced cases in which the degree of systemic inflammation was likely to be high due to an increased tumor burden, more than 70% of cases were classified into the group with an mGPS of 0. Although both the ALI and the mGPS are useful prognostic markers, there are still some subjects to be considered. Thus, it is difficult to decide which inflammatory marker is superior at the present time.

Although we set 28.9 as the cut-off value of the ALI based on the ROC curve in this study, the range of the cut-off values used in previous reports are relatively broad, with values of 18, 19.5 and 31.1 [11, 23, 24]. The degree of systemic inflammation was reported to be associated with the tumor progression, as with the TNM stage [3]. In addition, even at the same stage, the degree of inflammation may vary depending on the type of cancer. Therefore, the cut-off value of the ALI used in the present study is a provisional value. In this study, an ROC curve analysis, in which the vital status at the median survival was used as the state variable, was performed to determine the optimal cut-off ALI value. Although there were some patients who died within 6 months after the initiation of chemotherapy, the proportion of such patients was only 6.9%, and in many cases long-term follow-up was possible. Thus, the method used in this study to determine the cut-off value was thought to be relatively reliable.

The current study was a retrospective study with a small cohort in single-center. Further prospective studies are required to confirm our findings. In addition, it is necessary to determine the cut-off value for each type of cancer and stage in order to apply the ALI in the clinical setting.

When considering treatment strategies, the contents of treatment should be mainly decided according to the National Comprehensive Cancer Network or European Society for Medical Oncology guidelines, which are based on large-scale clinical data, rather than inflammatory markers such as the ALI. However, the present study—which was based on clinical data—revealed that ALI was a useful preoperative marker in patients with metastatic colorectal cancer and that inflammation was contributed to the cancer development and chemoresistance, both of which are meaningful findings.

Conclusions
A newly developed prognostic marker, the ALI, which is based on the BMI, serum albumin concentration and NLR, was found to be a novel prognostic marker in patients with unresectable metastatic colorectal cancer as well as in patients with lung cancer. Our findings indicate that the ALI may provide useful information when considering treatment strategies for unresectable metastatic colorectal cancer.

Table 4 The relationships between the ALI and discontinuation due to adverse events

| ALI                   | Without (n = 124) | With (n = 35) | P-value |
|-----------------------|-------------------|--------------|---------|
| ALI                   | Median (range)    |              |         |
| 38.06 (4.68–174.81)  | 31.45 (4.61–175.07) | 0.188       |

Abbreviations
ALI: Advanced lung cancer inflammation index; BMI: Body mass index; CapeOX: Capecitabine+oxaliplatin; CI: Confidence interval; CRP/ALB ratio: C-reactive protein to albumin ratio; CT: Computed tomography; FOLFIRI: 5-fluorouracil+leucovorin+irinotecan; FOLFOX: 5-fluorouracil+leucovorin +oxaliplatin; LMR: Lymphocyte to monocyte ratio; mGPS: Modified Glasgow prognostic score; NLR: Neutrophil to lymphocyte ratio; PMI: Psoas muscle mass index; PS: Performance status; ROC curve: Receiver operating characteristic curve; SOX: 5-1 + oxaliplatin

Acknowledgements
This research received no specific grants from any funding agency in the public, commercial or not-for-profit sectors. We thank Brian Quinn who provided medical writing services on behalf of JMC, Ltd.

Funding
No funding was acquired for this study.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
MS and KM designed the study, performed the statistical analysis and draft the manuscript. HN, TF, SM, KK and RA collected the clinical data and revised the manuscript critically. KH and MO designed the study and critically reviewed the manuscript. All authors read and approved the final manuscript.

Fig. 7 The correlation between the body mass index (BMI) and the psoas muscle mass index (PMI). The BMI was significantly associated with the PMI (r = 0.437, p < 0.001)
Ethics approval and consent to participate
This research conformed to the provisions of the Declaration of Helsinki. Written informed consent was obtained from all participants. This retrospective study was approved by our institutional review board (approval No.926).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 26 September 2017 Accepted: 13 March 2019
Published online: 18 March 2019

References
1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.
2. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121:2373–80.
3. Shibutani M, Maeda K, Nagahara H, Ohtani H, Shibuya N, Kubo N, Tanaka H, Muroga K, Ohira M, Hirakawa K. A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer. Anticancer Res. 2013;33:3291–4.
4. Galizia G, Lieto E, Zamboli A, De Vita F, Castellano P, Romano C, Auricchio A, Cardella F, De Stefano L, Orditura M. Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: A propensity score-matched analysis. Surgery. 2015;158:112–20.
5. Shibutani M, Maeda K, Nagahara H, Ohtani H, Sakurai K, Yamazoe S, Kimura K, Toyokawa T, Amato R, Tanaka H, Muroga K, Hirakawa K. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer. World J Gastroenterol. 2015;21:9966–73.
6. Chan JC, Chan DL, Diakos CI, Engel A, Pavlakis N, Gill A, Clarke SJ. The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer. Ann Surg. 2017;265:539–46.
7. Roxburgh CS, Crozier JE, Maxwell F, Fouks AK, Brown J, Mckee RF, Anderson JD, Horgan PG, McMillan DC. Comparison of tumour-based (Petersen Index) and inflammation-based (Glasgow Prognostic Score) scoring systems in patients undergoing curative resection for colon cancer. Br J Cancer. 2009;100:701–6.
8. Liu Y, He X, Pan J, Chen S, Wang L. Prognostic role of Glasgow prognostic score in patients with colorectal cancer: evidence from population studies. Sci Rep. 2017;7:5644.
9. Shibutani M, Maeda K, Nagahara H, Iseki Y, Ikeya T, Hirakawa K. Prognostic Significance of the Preoperative Ratio of C-Reactive Protein to Albumin in Patients with Colorectal Cancer. Anticancer Res. 2016;36:995–1001.
10. Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Ikeya T, Hirakawa K. Prognostic Significance of the C-Reactive Protein to Albumin Ratio for Survival After Surgery for Colorectal Cancer. Ann Surg Oncol. 2016;23:900–7.
11. Jafari SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer. 2013;13:158.
12. Kim EY, Kim YS, Park I, Ahn HK, Cho EK, Jeong YM. Prognostic significance of CT-determined sarcopenia in patients with small-cell lung Cancer. J Thorac Oncol. 2015;10:1795–9.
13. Kim EY, Kim YS, Seo JY, Park I, Ahn HK, Jeong YM, Kim JH, Kim N. The relationship between sarcopenia and systemic inflammatory response for Cancer Cachexia in small cell lung Cancer. PLoS One. 2016;11:e0161125.
14. Levolger S, van Vuurt JL, de Bruin RW, Uzermans JN. Systematic review of sarcopenia in patients operated on for gastrointestinal and hepatopancreato-biliary malignancies. Br J Surg. 2015;102:1448–58.
15. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figuer A, Wong R, Koski S, Lichtenste M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/leucovorin, or fluorouracil plus oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomized phase 3 trial. Lancet Oncol. 2013;14:1278–86.
16. Shibutani M, Maeda K, Nagahara H, Ohtani H, Sakurai K, Yamazoe A, Kimura K, Toyokawa T, Amato R, Kubo N, Tanaka H, Muroga K, Ohira M, Hirakawa K. Significance of Markers of Systemic Inflammation for Predicting Survival and Chemotherapeutic Outcomes and Monitoring Tumor Progression in Patients with Unresectable Metastatic Colorectal Cancer. Anticancer Res. 2015;35:5037–46.
17. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.
18. Guthrie GJ, Roxburgh CS, Horgan PG, McMillan DC. Does interleukin-6 link the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer? Cancer Treat Rev. 2013;39:899–96.
19. Elina N, Nowarski R, Thaisis CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759–71.
20. Hamaguchi Y, Kaido T, Okumura S, Kobayashi A, Hammad A, Tanai Y, Inagaki N, Uemoto S. Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults. Nutrition. 2016;22:1200–5.
21. Kim EY, Kim N, Kim YS, Seo JY, Park I, Ahn HK, Jeong YM, Kim JH. Prognostic significance of modified advanced lung Cancer inflammation index (ALI) in patients with small cell lung cancer comparison with original ALI. PLoS One. 2016;11:e0164056.
22. He X, Zhou T, Yang Y, Hong S, Zhan J, Hu Z, Fang W, Qin T, Ma Y, Zhao Y, Cheng Z, Huang Y, Zhao H, Yang G, Zhang L. Advanced Lung Cancer Inflammation Index, a New Prognostic Score, Predicts Outcome in Patients With Small-Cell Lung Cancer. Clin Lung Cancer. 2015;16:e165–71.